These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39030085)

  • 1. A Randomised Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-10 Brain Metastases.
    Whitfield GA; Bulbeck H; Clifton-Hadley L; Edwards D; Jefferies S; Jenkinson MD; Griffin M; Handley J; Megias D; Sanghera P; Shaffer R; Short S; Wilson W
    Clin Oncol (R Coll Radiol); 2024 Nov; 36(11):681-689. PubMed ID: 39030085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
    Chia BSH; Leong JY; Ong ALK; Lim C; Poon SH; Chua MLK; Chua KLM; Kusumawidjaja G; Chua ET; Wong FY; Lee TS
    BMC Cancer; 2020 Oct; 20(1):1045. PubMed ID: 33126867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance.
    Martinage G; Hong AM; Fay M; Thachil T; Roos D; Williams N; Lo S; Fogarty G
    Radiat Oncol; 2018 Jul; 13(1):132. PubMed ID: 30029684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
    Grosu AL; Frings L; Bentsalo I; Oehlke O; Brenner F; Bilger A; Fennell JT; Rothe T; Schneider-Fuchs S; Graf E; Schmoor C; Beck J; Becker G; Bock M; Egger K; Urbach H; Lahmann C; Popp I
    BMC Cancer; 2020 Jun; 20(1):532. PubMed ID: 32513138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Poor-Prognosis Patients with One to 10 Brain Metastases: A Randomised Feasibility Study.
    Raman S; Mou B; Hsu F; Valev B; Cheung A; Vallières I; Ma R; McKenzie M; Beaton L; Rackley T; Gondara L; Nichol A
    Clin Oncol (R Coll Radiol); 2020 Jul; 32(7):442-451. PubMed ID: 32085923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
    Chang EL; Wefel JS; Hess KR; Allen PK; Lang FF; Kornguth DG; Arbuckle RB; Swint JM; Shiu AS; Maor MH; Meyers CA
    Lancet Oncol; 2009 Nov; 10(11):1037-44. PubMed ID: 19801201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippocampal-sparing radiotherapy and neurocognitive impairment: A systematic literature review.
    Giuseppe ZR; Silvia C; Eleonora F; Gabriella M; Marica F; Silvia C; Mario B; Francesco D; Savino C; Milly B; Frezza GP; Maurizio Z; Morganti AG
    J Cancer Res Ther; 2020; 16(6):1215-1222. PubMed ID: 33342776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.
    Gondi V; Pugh SL; Tome WA; Caine C; Corn B; Kanner A; Rowley H; Kundapur V; DeNittis A; Greenspoon JN; Konski AA; Bauman GS; Shah S; Shi W; Wendland M; Kachnic L; Mehta MP
    J Clin Oncol; 2014 Dec; 32(34):3810-6. PubMed ID: 25349290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study.
    Tsai PF; Yang CC; Chuang CC; Huang TY; Wu YM; Pai PC; Tseng CK; Wu TH; Shen YL; Lin SY
    Radiat Oncol; 2015 Dec; 10():253. PubMed ID: 26654128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
    Tsao MN; Xu W; Wong RK; Lloyd N; Laperriere N; Sahgal A; Rakovitch E; Chow E
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD003869. PubMed ID: 29365347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
    Zindler JD; Bruynzeel AME; Eekers DBP; Hurkmans CW; Swinnen A; Lambin P
    BMC Cancer; 2017 Jul; 17(1):500. PubMed ID: 28743240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
    Tsao MN; Lloyd N; Wong RK; Chow E; Rakovitch E; Laperriere N; Xu W; Sahgal A
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003869. PubMed ID: 22513917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions: A preliminary report of a prospective phase II study.
    Lin SY; Yang CC; Wu YM; Tseng CK; Wei KC; Chu YC; Hsieh HY; Wu TH; Pai PC; Hsu PW; Chuang CC
    Biomed J; 2015; 38(5):439-49. PubMed ID: 25994802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis.
    Fuentes R; Osorio D; Expósito Hernandez J; Simancas-Racines D; Martinez-Zapata MJ; Bonfill Cosp X
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012086. PubMed ID: 30125049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer.
    Westover KD; Mendel JT; Dan T; Kumar K; Gao A; Pulipparacharuv S; Iyengar P; Nedzi L; Hannan R; Anderson J; Choe KS; Jiang W; Abdulrahman R; Rahimi A; Folkert M; Laine A; Presley C; Cullum CM; Choy H; Ahn C; Timmerman R
    Neuro Oncol; 2020 Dec; 22(12):1831-1839. PubMed ID: 32347302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
    Yang WC; Chen YF; Yang CC; Wu PF; Chan HM; Chen JL; Chen GY; Cheng JC; Kuo SH; Hsu FM
    Neuro Oncol; 2021 Mar; 23(3):478-486. PubMed ID: 32789503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosurgery versus surgery, both with adjuvant whole brain radiotherapy, for solitary brain metastases: a randomised controlled trial.
    Roos DE; Smith JG; Stephens SW
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):646-51. PubMed ID: 21592754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial.
    Zeng M; Verma V; Chen X; Li S; Sun Y; Liu G; Tian X; Zhang D; Li J; Liu Y; Liao X; Liu Y; Wang L; Wang X; Shi H; Li B; Xue B; Luo X
    Radiother Oncol; 2024 Aug; 197():110334. PubMed ID: 38801945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment planning strategy for whole-brain radiotherapy with hippocampal sparing and simultaneous integrated boost for multiple brain metastases using intensity-modulated arc therapy.
    Pokhrel D; Sood S; McClinton C; Shen X; Lominska C; Saleh H; Badkul R; Jiang H; Mitchell M; Wang F
    Med Dosim; 2016 Winter; 41(4):315-322. PubMed ID: 27692518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose specification for hippocampal sparing whole brain radiotherapy (HS WBRT): considerations from the UK HIPPO trial QA programme.
    Megias D; Phillips M; Clifton-Hadley L; Harron E; Eaton DJ; Sanghera P; Whitfield G
    Br J Radiol; 2017 Mar; 90(1071):20160829. PubMed ID: 28059560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.